LKFT: Lakefront Biotherapeutics NV insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
78 institutions reported holding $959.10M of Lakefront Biotherapeutics NV on Form 13F (90 the quarter before). 10 opened a new position and 21 sold out. Shares held by institutions: +3%.
| Largest holders | Shares | Value |
|---|---|---|
| GILEAD SCIENCES, INC. | 16,707,477 | $500.16M |
| TANG CAPITAL MANAGEMENT LLC | 3,785,991 | $113.50M |
| Madison Avenue Partners, LP | 3,447,807 | $103.37M |
| Prosight Management, LP | 2,043,344 | $61.26M |
| EcoR1 Capital, LLC | 1,667,119 | $49.98M |
| AMERIPRISE FINANCIAL INC | 1,272,249 | $38.14M |
| DME Capital Management, LP | 482,746 | $14.47M |
| RENAISSANCE TECHNOLOGIES LLC | 407,800 | $12.23M |
| BlackRock, Inc. | 338,152 | $10.14M |
| Point72 Asset Management, L.P. | 269,814 | $8.09M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.